DAVID M MOTT
CIK 1219871 · Vice Chair. of the Board, CEO · last filed 2026-02-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$4.68B
Companies
38
Total Filings
208
Lifetime Open-Market Net
$324.27M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARDX | Director | 6,785,104 | $5.69 | $38.61M | $65.06M | 30 | 2026-02-23 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | Director | 0 | $29.08 | $0 | $33.01M | 25 | 2026-01-06 |
| NVAX | Director | 60,890 | $8.88 | $540.7K | -$6.31M | 10 | 2025-06-24 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 19,500,000 | $0.06 | $1.13M | $5.00M | 6 | 2024-07-01 |
| Epizyme, Inc. (EPZM) Delisted | Director | 331,447 | $1.47 | $487.2K | $30.27M | 37 | 2022-07-05 |
| IMRA | Director | 229,224 | $17.02 | $3.90M | $313.6K | 6 | 2022-06-03 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 2,052,454 | $8.16 | $16.75M | $1.23M | 2 | 2019-12-26 |
| NET | 10%+ Owner | 4,059,376 | $228.48 | $927.49M | $0 | 1 | 2019-09-18 |
| MIRM | 10%+ Owner | 3,736,243 | $99.34 | $371.18M | $6.75M | 1 | 2019-07-24 |
| ASND | Director | 12,000,000 | $218.06 | $2.62B | $49.02M | 8 | 2019-07-03 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 7,225,676 | $0.00 | $4.3K | $14.69M | 2 | 2019-06-25 |
| NITE | Director | 0 | $37.45 | $0 | $0 | 2 | 2019-06-07 |
| TRVI | 10%+ Owner | 2,938,562 | $14.21 | $41.76M | $25.00M | 1 | 2019-05-13 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 25,243,865 | $15.00 | $378.66M | $17.12M | 15 | 2019-04-08 |
| TESARO, Inc. (TSRO) Delisted | Director | 0 | — | — | $73.35M | 10 | 2019-01-22 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | 10%+ Owner | 6,641,634 | $0.07 | $465.6K | $90.00M | 1 | 2018-10-24 |
| ESTC | 10%+ Owner | 4,155,995 | $60.35 | $250.81M | $0 | 1 | 2018-10-10 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,179,544 | $1.07 | $3.40M | $2.00M | 1 | 2018-04-23 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 8,949 | $24.01 | $214.9K | -$66.07M | 4 | 2018-02-15 |
| SYBX | 10%+ Owner | 4,228,940 | $0.69 | $2.92M | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 504 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $88.38 | $385.33M | $9.35M | 1 | 2017-10-10 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 2,576,939 | — | — | $0 | 1 | 2017-03-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 1,858,450 | — | — | $4.39M | 1 | 2016-10-31 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 3,216,810 | — | — | $4.60M | 3 | 2016-09-30 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,499,166 | — | — | $6.00M | 1 | 2015-10-06 |
| BOX | 10%+ Owner | 0 | $25.39 | $0 | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 0 | $8.52 | $0 | -$46.25M | 6 | 2014-11-28 |
| DERM | 10%+ Owner | 3,502,922 | $6.34 | $22.21M | $1.11M | 1 | 2014-10-08 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 575 | $0.08 | $47 | $17.11M | 2 | 2013-06-05 |
| WDAY | 10%+ Owner | 1,171 | $130.80 | $153.2K | $0 | 2 | 2013-04-11 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
| MEDI | Vice Chair. of the Board, CEO | 599,355 | $31.04 | $18.60M | $0 | 5 | 2007-06-19 |
Recent Filings · Page 2 of 21
208 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-02-26 | ARDX | Buy (P) | +77,729 | $388.7K | EDGAR |
| 2025-01-22 | ARDX | Buy (P) | +199,000 | $992.7K | EDGAR |
| 2024-12-27 | ARDX | Exer (M) | +100,000 | $55.0K | EDGAR |
| 2024-12-23 | ARDX | Buy (P) | +213,300 | $996.6K | EDGAR |
| 2024-11-14 | ARDX | Buy (P) | +215,868 | $996.6K | EDGAR |
| 2024-07-01 | Adaptimmune Therapeutics PLC (ADAP) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | ARDX | Grant (A) | +17,322 | $0 | EDGAR |
| 2024-06-14 | NVAX | Mixed | +6,670 | $0 | EDGAR |
| 2024-06-12 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-04 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | +8,810 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.